Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 5:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 511 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Relapsed and/or Refractory Multiple Myeloma Clear all
Completed Phase 2 Interventional Results available

Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT01096342
View directory record Official record
Conditions
Refractory Multiple Myeloma
Interventions
dinaciclib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Sep 15, 2026, 5:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

NCT04000282
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
SAR442085
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 15, 2026, 5:17 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

NCT03989414
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-92480, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib, Elotuzumab, Isatuximab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
16
States / cities
Denver, Colorado • Tampa, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 15, 2026, 5:17 PM EDT
Terminated Phase 1 Interventional

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

NCT04405167
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Tasquinimod, IRd chemotherapy
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 15, 2026, 5:17 PM EDT
Completed Phase 1 Interventional

A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib

NCT00689507
View directory record Official record
Conditions
Multiple Myeloma
Interventions
LY2127399
Biological
Lead sponsor
Applied Molecular Evolution
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Sep 15, 2026, 5:17 PM EDT
Completed Phase 2 Interventional

Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma

NCT01148108
View directory record Official record
Conditions
Mantle Cell Lymphoma, B Cell Lymphoma, Multiple Myeloma
Interventions
Canfosfamide HCl for injection
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Sep 15, 2026, 5:17 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

NCT03464916
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
CAR2 Anti-CD38 A2 CAR-T Cells
Biological
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Jacksonville, Florida • Rochester, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 15, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma

NCT00429949
View directory record Official record
Conditions
Relapsed, Refractory or Plateau Phase Multiple Myeloma
Interventions
Dasatinib
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Sep 15, 2026, 5:17 PM EDT
Completed Phase 1 Interventional

EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer

NCT00004258
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cilengitide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Sep 15, 2026, 5:17 PM EDT
Completed Phase 2 Interventional

Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00482495
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bevacizumab, gene expression analysis, protein expression analysis, laboratory biomarker analysis
Biological · Genetic · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 10, 2011 · Synced Sep 15, 2026, 5:17 PM EDT
Completed Phase 1 Interventional

XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease

NCT01582295
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cabozantinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Sep 15, 2026, 5:17 PM EDT
Active, not recruiting Phase 1 Interventional

Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

NCT03672318
View directory record Official record
Conditions
Multiple Myeloma, Immune System Diseases
Interventions
CAR138 T Cells
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2039
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 15, 2026, 5:17 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

NCT07409246
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ABBV-438
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 15, 2026, 5:17 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

NCT02278315
View directory record Official record
Conditions
Multiple Myeloma
Interventions
I-131-CLR1404, dexamethasone
Drug
Lead sponsor
Cellectar Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
4
States / cities
Jacksonville, Florida • Maywood, Illinois • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 15, 2026, 5:17 PM EDT
Active, not recruiting Phase 1 Interventional

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

NCT05391750
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Tocilizumab, Venetoclax
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 15, 2026, 5:17 PM EDT
Terminated Phase 1 Interventional Results available

Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00687674
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
dexamethasone, sorafenib tosylate, Lenalidomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 15, 2026, 5:17 PM EDT
Not listed Phase 2 Interventional

Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment

NCT00389701
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bortezomib, dexamethasone
Drug
Lead sponsor
Sparrow Regional Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Sep 15, 2026, 5:17 PM EDT
Completed Phase 1 Interventional

Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma

NCT00972712
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib and Tipifarnib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
2
States / cities
Duarte, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Sep 15, 2026, 5:17 PM EDT
Completed Phase 2 Interventional

A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

NCT00096837
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Motexafin Gadolinium Injection
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 7, 2006 · Synced Sep 15, 2026, 5:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

NCT07479979
View directory record Official record
Conditions
Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Selinexor, Carfilzomib, Isatuximab, Isatuximab SC Wearable Injection System, Dexamethasone
Drug · Device
Lead sponsor
Natalie Callander
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 15, 2026, 5:17 PM EDT
Terminated No phase listed Observational

Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

NCT00813501
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Neuroblastoma, Therapy-related Toxicity
Interventions
immunosuppressive therapy, immunological diagnostic method, allogeneic hematopoietic stem cell transplantation
Biological · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2011 · Synced Sep 15, 2026, 5:17 PM EDT
Active, not recruiting Phase 1 Interventional

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT01562405
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ACE-011, Lenalidomide, Dexamethasone, Pomalidomide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 15, 2026, 5:17 PM EDT
Not listed Phase 1 Interventional

Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma

NCT00821301
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Fluphenazine HCl
Drug
Lead sponsor
Immune Control
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2009 · Synced Sep 15, 2026, 5:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

NCT00474929
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
RAD001, Sorafenib
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
2
States / cities
Iowa City, Iowa • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 15, 2026, 5:17 PM EDT